Hostname: page-component-78c5997874-dh8gc Total loading time: 0 Render date: 2024-11-02T19:23:26.324Z Has data issue: false hasContentIssue false

Breast cancer risk prediction accuracy in Jewish Israeli high-risk women using the BOADICEA and IBIS risk models

Published online by Cambridge University Press:  10 February 2014

YAEL LAITMAN
Affiliation:
The Susanne Levy Gertner Oncogenetics Unit, Tel-Aviv University, Tel-Aviv, Israel
MONICA SIMEONOV
Affiliation:
The Susanne Levy Gertner Oncogenetics Unit, Tel-Aviv University, Tel-Aviv, Israel
LITAL KEINAN-BOKER
Affiliation:
The Israeli National Cancer Registry, Ministry of Health, Tel-Aviv University, Tel -Aviv, Israel The School of Public Health, University of Haifa, Tel-Aviv University, Tel -Aviv, Israel
IRENA LIPHSHITZ
Affiliation:
The Israeli National Cancer Registry, Ministry of Health, Tel-Aviv University, Tel -Aviv, Israel
EITAN FRIEDMAN*
Affiliation:
The Susanne Levy Gertner Oncogenetics Unit, Tel-Aviv University, Tel-Aviv, Israel The Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel
*
* Corresponding author: The Susanne Levy Gertner Oncogenetics Unit, The Danek Gertner Institute of Human Genetics, Chaim Sheba Medical Center, Tel-Hashomer, 52621, Israel. Tel: +972-3-530-3173. Fax: +972-3-535-7308. E-mail: [email protected] or [email protected]

Summary

Several breast cancer risk prediction models have been validated in ethnically diverse populations, but none in Israeli high-risk women. To validate the accuracy of the IBIS and BOADICEA risk prediction models in Israeli high-risk women, the 10-year and lifetime risk for developing breast cancer were calculated using both BOADICEA and IBIS models for high-risk, cancer-free women, counselled at the Sheba Medical Center from 1 June 1996–31 May 2000. Women diagnosed with breast cancer by 31 May 2011 were identified from the Israeli National Cancer Registry. The observed to expected breast cancer ratios were calculated to evaluate the predictive value of both algorithms. Overall, 358 mostly (N = 205, 57·2%) Ashkenazi women, were eligible, age range at counselling was 20–75 years (mean 46·76 ± 9·8 years). Over 13·6 ± 1·45 years (range 11–16 years), 15 women (4·19%) were diagnosed with breast cancer, at a mean age of 57 ± 8·6 years. The 10-year risks assigned by BOADICEA and IBIS ranged from 0·2 to 12·6% and 0·89 to 21·7%, respectively. The observed:expected breast cancer ratio was 15/18·6 (0·8–95% CI 0·48–1·33) and 15/28·6 (0·52–95% CI 0·32–0·87), using both models, respectively. In Jewish Israeli high-risk women the BOADICEA model has a better predictive value and accuracy in determining 10-year breast cancer risk than the IBIS model.

Type
Research Papers
Copyright
Copyright © Cambridge University Press 2014 

1. Introduction

Schemes for early detection of breast cancer in average-risk women include mammography screening every 2 years and a physician-guided breast exam every year from age 50 years. For high-risk women, in particular those with known mutations in the major breast cancer susceptibility genes, BRCA1, BRCA2 and a family history of cancer, who have a 20% or greater lifetime risk for developing breast cancer, most guidelines recommend annual breast MRI and a 6-month breast exam starting at age 30 years (Smith et al., Reference Smith, Cokkinides, Brooks, Saslow, Shah and Brawley2011; http://publications.nice.org.uk/familial-breast-cancer-cg164/). In addition, the Breast Cancer Risk Assessment Tool (BCRAT) is used to determine whether a woman meets the minimum risk threshold of a 5-year risk of at least 1·67% when tamoxifen treatment for primary chemoprevention is considered (Fisher et al., Reference Fisher, Costantino, Wickerham, Cecchini, Cronin, Robidoux, Bevers, Kavanah, Atkins, Margolese, Runowicz, James, Ford and Wolmark2005; Smith et al., Reference Smith, Cokkinides, Brooks, Saslow, Shah and Brawley2011). Thus, an objective assessment of a woman's breast cancer risk has obvious clinical implications that affect management decisions.

Several statistical models have been developed for assessing risk for developing breast cancer (Gail et al., Reference Gail, Brinton, Byar, Corle, Green, Schairer and Mulvihill1989, Reference Gail, Costantino, Pee, Bondy, Newman, Selvan, Anderson, Malone, Marchbanks, McCaskill-Stevens, Norman, Simon, Spirtas, Ursin and Bernstein2007; Claus et al., Reference Claus, Risch and Thompson1993; Antoniou et al., Reference Antoniou, Pharoah, Smith and Easton2004; Tyrer et al., Reference Tyrer, Duffy and Cuzick2004). These models are based on algorithms that take into account factors such as family history of breast/ovarian cancer, BRCA1/BRCA2 carrier status, and non-genetic risk factors, such as current age, age at menarche, age at first live birth, number of previous breast biopsies, history of atypical hyperplasia, race/ethnicity, height and weight, use of hormone replacement therapy and number of affected female first- and second-degree relatives (Gail et al., Reference Gail, Brinton, Byar, Corle, Green, Schairer and Mulvihill1989, Reference Gail, Costantino, Pee, Bondy, Newman, Selvan, Anderson, Malone, Marchbanks, McCaskill-Stevens, Norman, Simon, Spirtas, Ursin and Bernstein2007; Bondy et al., Reference Bondy, Lustbader, Halabi, Ross and Vogel1994; Costantino et al., Reference Costantino, Gail, Pee, Anderson, Redmond, Benichou and Wieand1999; Tyrer et al., Reference Tyrer, Duffy and Cuzick2004; Matsuno et al., Reference Matsuno, Costantino, Ziegler, Anderson, Li, Pee and Gail2011). For example, the BCRAT (also known as Gail model); the International Breast cancer Intervention study (IBIS- http://www.ems-trials.org/riskevaluator/) also known as the Tyrer–Cusick risk evaluator; the Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm (BOADICEA – http://ccge.medschl.cam.ac.uk/boadicea/). Notably, not all three models take into account all of these breast cancer risk factors or similarly weight them when assigning breast cancer risk. These risk assignment models have been validated in several cohorts, both average-risk and high-risk individuals in several ethnically diverse populations (Spiegelman et al., Reference Spiegelman, Colditz, Hunter and Hertzmark1994; Jacobi et al., Reference Jacobi, de Bock, Siegerink and van Asperen2009; Matsuno et al., Reference Matsuno, Costantino, Ziegler, Anderson, Li, Pee and Gail2011; Anothaisintawee et al., Reference Anothaisintawee, Teerawattananon, Wiratkapun, Kasamesup and Thakkinstian2012). None has been assessed in a Jewish Israeli high-risk population and in most cases the cohorts included both high-risk and average-risk women, and BRCA mutation carriers were not excluded. Since the BCRAT model has not been recommended for use in high-risk women or for women under the age of 35 years, we elected to evaluate the accuracy of the BOADICEA and IBIS models in high-risk women of that ethnic group.

2. Materials and methods

2.1 Study population

All women who underwent oncogenetic counselling from 1 June 1996 to 31 May 2000 at the Oncogenetics unit at the Sheba Medical Center, Tel-Hashomer were eligible if they fulfilled the inclusion criteria: were cancer free at the time of initial counselling; were considered high risk based on the accepted practiced clinical criteria, as previously described by us (Kushnir et al., Reference Kushnir, Laitman, Paluch-Shimon, Berger and Friedman2012); and were genotyped for the predominant mutations in BRCA1 and BRCA2 in Jewish women and tested negative. The study was approved by the local IRB of the Sheba Medical Center, and each participant gave her informed consent.

2.2 Assignment of risk for developing breast cancer

The 10-year and lifetime risks for developing breast cancer were calculated for all eligible participants using the freely available algorithms of BOADICEA (http://ccge.medschl.cam.ac.uk/boadicea/) and IBIS (http://www.ems-trials.org/riskevaluator/ – version 6).

2.3 Follow-up

Counselling date indicated the beginning of follow-up for each participant. End of follow-up was marked by breast cancer diagnosis date or by the end of the follow-up (1 May 2011), whichever came first.

2.4 Calculating the observed/expected ratio of breast cancer

Observed breast cancer rates were obtained from the Israeli National Cancer Registry (INCR) by cross referencing the ID numbers of all participants with the list of breast cancer diagnoses reported to the INCR. The INCR, a passive, national, population-based cancer registry, was established in 1960. Since 1982 reporting on all cancer cases to the INCR is compulsory by law. The INCR completeness with respect to solid tumours is over 93% (Fishler et al., Reference Fishler, Barchana, Keinan-Boker, Ifrah and Blau2008). The expected rates of developing breast cancer for the study participants were calculated separately from each algorithm. To that end, the predicted 10 year risk for each participant was divided by 10 to obtain the annual risk, and then multiplied by the number of years since initial counselling to the time of evaluation (11–16 years). The expected number of breast cancer cases in the cohort is the sum of all these predicted risks. The observed/expected ratio was then calculated. The 95% confidence interval was calculated by using the Poisson distribution.

3. Results

3.1 Study population

Overall, 358 Jewish Israeli women participated in the study: 205 (57·2%) were of Ashkenazi origin; age range at counselling was 20–75 years (mean age 46·76 ± 9·8 years). The average follow-up was 13·57 ± 1·45 years (range 11–16 years), with a total of 4·861 person-years of follow-up. During that time period 15 women (4·18%) were diagnosed with breast cancer, mean age at diagnosis was 57·06 ± 8·6 years (range 37–74 years).

3.2 IBIS and BOADICEA breast cancer risks

Table 1 shows the ranges and the means of the predicted risks for breast cancer, at 10-year, during the calculated study duration, and lifetime risk using both models for women who developed breast cancer and those who remained cancer-free at the end of the follow-up.

Table 1. Predicted risk for breast cancer at 10 years, for the duration of the study and lifetime, based on the IBIS and BOADICEA models, by health status

a BC – Denotes breast cancer.

b The 10-year risk divided by 10.

c The 10-year risk divided by 10 and multiplied by the duration of the study follow-up per individual.

d The 10-year risk and lifetime risk multiplied by 100.

3.3 Observed/expected breast cancer ratio

Using the IBIS model, the observed/expected ratio was 15/28·6 = 0·52 (95% CI 0·32–0·87); using the BOADICEA model the observed/expected ratio was 15/18·7 = 0·52 (95% CI 0·48–1·33).

4. Discussion

In the present study, where validation of two prediction models for breast cancer risk was carried out in high-risk Israeli women, both models overestimated the actual risks.

However, the BOADICEA model outperformed the IBIS model as a predictor of breast cancer risk in this population of Jewish Israeli high-risk women. Several factors may have contributed to these differences in accuracy of breast cancer risk prediction: the inability to assess cancers other than breast and ovary in family members in the IBIS model, the inability (in version 6) to evaluate a male breast cancer cases, and the overestimation of the non-genetic risk factors in that algorithm compared with the BOADICEA model. These differences may also relate to the specific risks of Jewish high-risk women. Despite the fact that both models allow for including Ashkenazi ethnicity as a covariate, neither has been validated in Jewish non-Ashkenazi women, until the present study. In other populations, both models were rated as equally accurate and outperforming other available breast cancer risk models (Jacobi et al., Reference Jacobi, de Bock, Siegerink and van Asperen2009).

Determining lifetime risk for developing breast cancer has a clinical implication in Israel as the national health basket covers breast MRI from age 30 years to all women who have a 20% risk or more for developing breast cancer. Thus, using the more accurate risks assigned by BOADICEA may help in targeting the individuals who seems to be at the highest level of breast cancer risk, with little overspending of the resources. One of the main purposes of using these models is to assess eligibility for offering genetic testing for the high-risk women. The current guidelines stipulate that anyone with a 10–15% chance of having a BRCA1/BRCA2 mutation should be offered genetic testing and genotyped (Smith et al., Reference Smith, Cokkinides, Brooks, Saslow, Shah and Brawley2011). The limited spectrum of BRCA1/BRCA2 mutations in Jewish individuals, primarily (but not exclusively) of Ashkenazi origin, coupled with the paucity of ‘private’, family-specific germline mutations in both genes, and the fact that the risks for harbouring BRCA1/BRCA2 mutations in consecutive breast and ovarian cancer cases in Jewish individuals is well established (Laitman et al., Reference Laitman, Borsthein, Stoppa-Lyonnet, Dagan, Castera, Goislard, Gershoni-Baruch, Goldberg, Kaufman, Ben-Baruch, Zidan, Maray, Soussan-Gutman and Friedman2011), makes the application of both these models as determining genetic testing eligibility in Israel of limited clinical utility.

This study has several inherent limitations: the number of women is limited, despite the long-term follow-up and the number of cumulative person-years; it is a retrospective cohort study with all the disadvantages of this study design. All participants were recruited from a single medical centre in Israel which may not adequately represent the entire high-risk population in Israel. The fact that BRCA mutations tested were predominantly detected in Ashkenazi (and to a lesser extent Iraqi) high-risk families is also a limitation. Yet the rate of ‘private’ family-specific mutations in the Ashkenazi and non-Ashkenazi high-risk women is 4·7 and 8·8%, respectively (Laitman et al., Reference Laitman, Borsthein, Stoppa-Lyonnet, Dagan, Castera, Goislard, Gershoni-Baruch, Goldberg, Kaufman, Ben-Baruch, Zidan, Maray, Soussan-Gutman and Friedman2011). Thus, the majority of women tested are indeed non-BRCA mutation carriers.

In conclusion, the BOADICEA model outperformed the IBIS model in Jewish Israeli high-risk women in determining breast cancer risk. These data should be validated in a larger prospective cohort study setting.

This study was partially funded by the Israel Cancer Association through the Israeli Hereditary breast cancer consortium.

5. Conflict of interest statement

All authors declare that they have no conflict of interest regarding the data published.

References

Anothaisintawee, T., Teerawattananon, Y., Wiratkapun, C., Kasamesup, V. & Thakkinstian, A. (2012). Risk prediction models of breast cancer: a systematic review of model performances. Breast Cancer Research and Treatment 133, 110.Google Scholar
Antoniou, A. C., Pharoah, P. P., Smith, P. & Easton, D. F. (2004). The BOADICEA model of genetic susceptibility to breast and ovarian cancer. British Journal of Cancer 91, 15801590.Google Scholar
Bondy, M. L., Lustbader, E. D., Halabi, S., Ross, E. & Vogel, V. G. (1994). Validation of a breast cancer risk assessment model in women with a positive family history. Journal of the National Cancer Institute 86, 620625.CrossRefGoogle ScholarPubMed
Breast Cancer Risk Assessment Tool. Available at: http://www.cancer.gov/bcrisktool.Google Scholar
Claus, E. B., Risch, N. & Thompson, W. D. (1993). The calculation of breast cancer risk for women with a first degree family history of ovarian cancer. Breast Cancer Research and Treatment 28, 115120.CrossRefGoogle ScholarPubMed
Costantino, J. P., Gail, M. H., Pee, D., Anderson, S., Redmond, C. K., Benichou, J. & Wieand, H. S. (1999). Validation studies for models projecting the risk of invasive and total breast cancer incidence. Journal of the National Cancer Institute 91, 15411548.Google Scholar
Fisher, B., Costantino, J. P., Wickerham, D. L., Cecchini, R. S., Cronin, W. M., Robidoux, A., Bevers, T. B., Kavanah, M. T., Atkins, J. N., Margolese, R. G., Runowicz, C. D., James, J. M., Ford, L. G. & Wolmark, N. (2005). Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. Journal of the National Cancer Institute 97, 16521662.Google Scholar
Fishler, Y., Barchana, M., Keinan-Boker, L., Ifrah, A. & Blau, S. (2008). Cancer in Israel. Trends of incidence and mortality, 1982–2002, and update of selected data, 2004. Israel Center for Disease Control, Publication # 310 [Hebrew].Google Scholar
Gail, M. H., Brinton, L. A., Byar, D. P., Corle, D. K., Green, S. B., Schairer, C. & Mulvihill, J. J. (1989). Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. Journal of the National Cancer Institute 81, 18791886.CrossRefGoogle ScholarPubMed
Gail, M. H., Costantino, J. P., Pee, D., Bondy, M., Newman, L., Selvan, M., Anderson, G. L., Malone, K. E., Marchbanks, P. A., McCaskill-Stevens, W., Norman, S. A., Simon, M. S., Spirtas, R., Ursin, G. & Bernstein, L. (2007). Projecting individualized absolute invasive breast cancer risk in African American women. Journal of the National Cancer Institute 99, 17821792.Google Scholar
Jacobi, C. E., de Bock, G. H., Siegerink, B. & van Asperen, C. J. (2009). Differences and similarities in breast cancer risk assessment models in clinical practice: which model to choose? Breast Cancer Research and Treatment 115, 381390.Google Scholar
Kushnir, A., Laitman, Y., Paluch-Shimon, S., Berger, R. & Friedman, E. (2012). Germline mutations in RAD51C in Jewish high cancer risk families. Breast Cancer Research and Treatment 136, 869874.CrossRefGoogle ScholarPubMed
Laitman, Y., Borsthein, R. T., Stoppa-Lyonnet, D., Dagan, E., Castera, L., Goislard, M., Gershoni-Baruch, R., Goldberg, H., Kaufman, B., Ben-Baruch, N., Zidan, J., Maray, T., Soussan-Gutman, L. & Friedman, E. (2011). Germline mutations in BRCA1 and BRCA2 genes in ethnically diverse high risk families in Israel. Breast Cancer Research and Treatment 127, 489495.Google Scholar
Matsuno, R. K., Costantino, J. P., Ziegler, R. G., Anderson, G. L., Li, H., Pee, D. & Gail, M. H. (2011). Projecting individualized absolute invasive breast cancer risk in Asian and Pacific Islander American women. Journal of the National Cancer Institute 103, 951961.CrossRefGoogle ScholarPubMed
Smith, R. A., Cokkinides, V., Brooks, D., Saslow, D., Shah, M. & Brawley, O. W. (2011). Cancer screening in the United States, 2011: a review of current American Cancer Society guidelines and issues in cancer screening. CA: A Cancer Journal for Clinicians 61, 830.Google Scholar
Spiegelman, D., Colditz, G. A., Hunter, D. & Hertzmark, F. (1994). Validation of the Gail et al., model for predicting individual breast cancer risk. Journal of the National Cancer Institute 86, 600607.Google Scholar
Tyrer, J., Duffy, S. W. & Cuzick, J. (2004). A breast cancer prediction model incorporating familial and personal risk factors. Statistics in Medicine 23, 11111130.Google Scholar
Figure 0

Table 1. Predicted risk for breast cancer at 10 years, for the duration of the study and lifetime, based on the IBIS and BOADICEA models, by health status